Qiming Venture Partners

Qiming Venture Partners' portfolio company MedSci successfully listed on HKEX main board

Retrieved on: 
Thursday, April 27, 2023
Communication, IPO, Omnichannel, MAU, Life, Big data, Qiming Venture Partners, Research, RWS, Patient, Physician, Series, Knowledge, AI, Development, Hong Kong Stock Exchange, HK, Nursing, Pharmaceutical industry

SHANGHAI, April 27, 2023 /PRNewswire/ -- On April 27th Beijing time, Qiming Venture Partners' portfolio company MedSci Healthcare Holdings Limited("MedSci"), a leading physician digital platform in China, successfully listed on the main board of Hong Kong Stock Exchange.

Key Points: 
  • SHANGHAI, April 27, 2023 /PRNewswire/ -- On April 27th Beijing time, Qiming Venture Partners' portfolio company MedSci Healthcare Holdings Limited("MedSci"), a leading physician digital platform in China, successfully listed on the main board of Hong Kong Stock Exchange.
  • As of the IPO, Qiming was one of the major investors of MedSci.
  • MedSci's successful listing is also the sixth IPO that Qiming has welcomed since 2023.
  • MedSci has always been focused on this area and played an important role in the industry's development.

DeepWay Raises ￥770 Million in Series A+ Round to Accelerate Mass Production of Smart Electric Heavy-duty Truck and Further R&D Exploration

Retrieved on: 
Tuesday, March 28, 2023
Qiming Venture Partners, Shandong Weiqiao Pioneering Group, 199th, Multimedia, Carbon, Terra Venture Partners, Investment, Fortune Global 500, R, Transport, Environment, Automotive industry, Warehouse

BEIJING, March 28, 2023 /PRNewswire/ -- DeepWay company, a smart commercial vehicle developer and manufacturer, recently announced that it had raised a￥770 million Series A+ financing led by Shandong Weiqiao Pioneering Group ("Weiqiao Pioneering"), who ranked 199th on Fortune Global 500 in 2022 , and SB China Venture Capital ("SBCVC"), with participation from several existing investors, including Qiming Venture Partners. 

Key Points: 
  • DeepWay will tap into new round financing for the manufacture of smart electric heavy-duty truck and the R&D of intelligent driving systems to ensure mass production and high-quality delivery of DeepWay truck, which further consolidates the company's leadership position in the smart electric heavy truck market.
  • Weiqiao Pioneering, the world's largest aluminium producer, will also become one of the first customers of DeepWay's premium smart electric heavy-duty trucks.
  • We also plan to build a long-term, far-reaching relationship with DeepWay with the mindset of jointly embracing the era of smart logistics."
  • We also look forward to working together to create next-generation solutions for the new era of smart logistics."

TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery

Retrieved on: 
Wednesday, March 1, 2023
Research, General Health, Professional Services, Pharmaceutical, Technology, Artificial Intelligence, Science, Biotechnology, Finance, Consulting, Other Science, Health, MBA, Qiming Venture Partners, AI, ARCH Venture Partners, OrbiMed, Drug discovery, Artificial intelligence, Partner (business rank), Biology, Pharmaceutical industry, Cryptocurrency

TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced it has raised $35 million in a Series A financing to expand its drug discovery service platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry, and biology.

Key Points: 
  • TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced it has raised $35 million in a Series A financing to expand its drug discovery service platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry, and biology.
  • Qiming Venture Partners led the financing along with participation from OrbiMed, Eight Roads Ventures, and F Prime Capital.
  • “TandemAI has developed a compelling vision for drug discovery that leverages both best-in-class experimental and computational technologies,” said Jarlon Tsang, Managing Partner and Head of China for Eight Roads.
  • “Significantly, their integrated approach streamlines the discovery workflow and enables access to state-of-the-art computational tools for biotechnology companies at any stage and any scale.

Qiming Venture Partners' portfolio company LanzaTech Lists on Nasdaq

Retrieved on: 
Saturday, February 11, 2023
Partner, SPAC, Qiming Venture Partners, Plant, Lululemon Athletica, Carbon, Ethanol, CO2, Acquisition, Aviation biofuel, Total, IPO, Shougang Group, L'Oréal, Renewable energy, Unilever

SHANGHAI, Feb. 10, 2023 /PRNewswire/ -- LanzaTech NZ, Inc. ("LanzaTech"), an innovative leader in carbon capture and transformation and a Qiming Venture Partners portfolio company, listed on Nasdaq on Feb 10 Beijing time, following the completion of its business combination with AMCI Acquisition Corp. II ("AMCI"), a special purpose acquisition company.

Key Points: 
  • SHANGHAI, Feb. 10, 2023 /PRNewswire/ -- LanzaTech NZ, Inc. ("LanzaTech"), an innovative leader in carbon capture and transformation and a Qiming Venture Partners portfolio company, listed on Nasdaq on Feb 10 Beijing time, following the completion of its business combination with AMCI Acquisition Corp. II ("AMCI"), a special purpose acquisition company.
  • The combined company will operate as LanzaTech Global, Inc. (NASDAQ: LNZA).
  • As LanzaTech's early investor, Qiming led the company's series B round of financing in 2010 and followed on its Series C and D rounds.
  • " Said Gary Rieschel, Founding Managing Partner of Qiming Venture Partners.

Qiming Venture Partners Celebrates Hesai Technology's IPO on Nasdaq

Retrieved on: 
Thursday, February 9, 2023
Mechanics, D, Original equipment manufacturer, Partner, Electronics, ADAS, Software, Robotics, Social change, IPO, City, Elevate, Advanced driver-assistance system, Transport, Qiming Venture Partners, Lidar

SHANGHAI, Feb. 9, 2023 /PRNewswire/ -- On Feb 9 Beijing time, Hesai Technology ("Hesai"), a global leader in LiDAR technology and Qiming Venture Partners' portfolio company, began trading on Nasdaq.

Key Points: 
  • SHANGHAI, Feb. 9, 2023 /PRNewswire/ -- On Feb 9 Beijing time, Hesai Technology ("Hesai"), a global leader in LiDAR technology and Qiming Venture Partners' portfolio company, began trading on Nasdaq.
  • Hesai Technology (NASDAQ: HSAI) offered at $19/ADS and opened at $23.75/ADS, up by 25%, representing a market cap of $2.98 billion.
  • Back in 2019, Qiming invested in Hesai Technology's Series C round of financing and followed on in its Series D round.
  • "Qiming is honored to accompany Hesai's growth and delighted to see its IPO on Nasdaq, a milestone and a new beginning for the company.

China's Leading Adult Interest Learning Service Provider QuantaSing Group Limited Successfully Listed on Nasdaq

Retrieved on: 
Tuesday, January 31, 2023
Artificial intelligence, Learning, Knowledge, IPO, Growth, Qiming Venture Partners, Love, Video game

SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- On January 25, Beijing time, QuantaSing Group Limited, a Qiming Venture Partners portfolio company and China's leading online adult interest learning service provider, successfully listed on Nasdaq.

Key Points: 
  • SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- On January 25, Beijing time, QuantaSing Group Limited, a Qiming Venture Partners portfolio company and China's leading online adult interest learning service provider, successfully listed on Nasdaq.
  • QuantaSing Group Limited (NASDAQ:QSG) offered at $12.5/ADS and closed at $12.52/ADS with a market cap of $690 million.
  • QuantaSing is a provider of online learning services targeting adults.
  • According to Frost & Sullivan report, QuantaSing is the largest online learning service provider for adult interest learning in China, and one of the top five service providers in adult learning market in China based on revenue in 2021.

4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Retrieved on: 
Tuesday, December 6, 2022
Janus, DUB, Ubiquitin, Enzyme, Capital Markets Board of Turkey, Protein, ENTAC, Qiming Venture Partners, University of Liverpool, Dub, Medicine, Doctor of Philosophy, WEHI, Disease, Therapy, University, Patient, Encompass, Fine chemical, Citadel

The Series A financing follows an initial seed investment from 4BIO Capital and Arkin Bio Ventures who supported and incubated the company.

Key Points: 
  • The Series A financing follows an initial seed investment from 4BIO Capital and Arkin Bio Ventures who supported and incubated the company.
  • With broad utility across disease types, ENTACs have significant potential to expand the druggable space and address unmet medical needs.
  • Many diseases occur when there is a functional problem with a beneficial protein that is critical to cell health.
  • Ubiquitin plays a broad role in protein function, so tailored removal of ubiquitin can enhance the function of the target protein.

Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Pharmaceutical, Health, Janus, Therapy, Scale Venture Partners, Qiming Venture Partners, Medicine, Enzyme, Doctor of Philosophy, Protein, University of Liverpool, Patient, WEHI, Greve, Buhrlage, and Company, ENTAC, Disease, Ubiquitin, Bio, University, Biochemistry, DUB, Olivier Richon, Encompass, Dub, Fine chemical, Citadel

These ENTAC medicines will make an important difference for patients whose needs aren't adequately met by todays treatments.

Key Points: 
  • These ENTAC medicines will make an important difference for patients whose needs aren't adequately met by todays treatments.
  • Ubiquitin plays a broad role in protein function, so tailored removal of ubiquitin can enhance the function of the target protein.
  • Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins.
  • By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Kandou Appoints Needham & Company’s Hanqing (Helen) Li to its Board of Directors

Retrieved on: 
Thursday, November 17, 2022
Semiconductor, PCI Express, Qiming Venture Partners, IP, Electricity, Electronics, InvenSense, Marvell Technology Group, Electrical engineering, University, AI, Machine learning, MBA, USB, Senior, Needham & Company, Tsinghua University, Micron Technology, Research, MIT Sloan School of Management, Bachelor of Arts in Applied Psychology, Management

Helen Li is a welcome addition to the Kandou board, remarks Amin Shokrollahi, Founder and CEO of Kandou.

Key Points: 
  • Helen Li is a welcome addition to the Kandou board, remarks Amin Shokrollahi, Founder and CEO of Kandou.
  • Her exceptional knowledge and understanding of the semiconductor industry and international investment and banking expertise make her an ideal sounding board for our executives.
  • Kandou has all the characteristics of a successful, well-run technology company and Im pleased to join its board, Ms. Li comments.
  • The company was founded in 2011 and is headquartered in Lausanne, Switzerland, with offices in Europe, North America and Asia.

Qiming Venture Partners portfolio Transwarp successfully lists on STAR Market

Retrieved on: 
Tuesday, October 18, 2022
Venus, CanSino Biologics, Qiming Venture Partners, Health care, Government, Transport, Growth, Technology, Partner, NYSE, NASDAQ, HKEX, IPO, Shanghai Stock Exchange, Shenzhen Stock Exchange, RMB, San Francisco Bay Area, Software, Initial public offering, STAR, Industry, Big data, Information technology, CEO, UBtech Robotics, Gan, T&C, Mining, Bank, Security (finance), Warp drive

SHANGHAI, Oct. 17, 2022 /PRNewswire/ -- Transwarp, a Qiming Venture Partners portfolio company and China's leading software developer of enterprise big data infrastructure, successfully lists on the STAR board of Shanghai Stock Exchange today.

Key Points: 
  • SHANGHAI, Oct. 17, 2022 /PRNewswire/ -- Transwarp, a Qiming Venture Partners portfolio company and China's leading software developer of enterprise big data infrastructure, successfully lists on the STAR board of Shanghai Stock Exchange today.
  • Transwarp's successful IPO is also the 7th IPO for Qiming Venture Partners since the beginning of 2022.
  • Kuantai Yeh, Partner of Qiming Venture Partners, said, "I am glad to witness another milestone moment of Transwarp.
  • Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised.